Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Holdings Decreased by Candriam S.C.A.

Candriam S.C.A. trimmed its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 45.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 547,165 shares of the company’s stock after selling 451,454 shares during the quarter. Candriam S.C.A. owned approximately 0.64% of Syndax Pharmaceuticals worth $7,234,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in SNDX. Atria Investments Inc bought a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at approximately $364,000. Simplify Asset Management Inc. grew its stake in Syndax Pharmaceuticals by 62.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock worth $2,352,000 after buying an additional 46,992 shares during the last quarter. Quest Partners LLC grew its stake in Syndax Pharmaceuticals by 31.0% during the 3rd quarter. Quest Partners LLC now owns 17,858 shares of the company’s stock worth $344,000 after buying an additional 4,223 shares during the last quarter. First Turn Management LLC grew its stake in Syndax Pharmaceuticals by 85.4% during the 3rd quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock worth $22,853,000 after buying an additional 546,776 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Syndax Pharmaceuticals during the 3rd quarter worth $15,165,000.

Wall Street Analysts Forecast Growth

SNDX has been the subject of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $35.00 to $39.00 and gave the stock an “overweight” rating in a research note on Tuesday. Citigroup lowered their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday. Scotiabank reduced their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Finally, StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Insider Transactions at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the transaction, the insider now directly owns 85,095 shares of the company’s stock, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Keith A. Goldan sold 3,777 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the transaction, the chief financial officer now directly owns 90,746 shares in the company, valued at $1,406,563. The trade was a 4.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock valued at $336,087 over the last three months. Company insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Stock Down 6.1 %

Shares of Syndax Pharmaceuticals stock opened at $13.42 on Friday. The stock’s fifty day moving average is $14.33 and its 200-day moving average is $16.63. The firm has a market capitalization of $1.15 billion, a PE ratio of -3.70 and a beta of 0.90. Syndax Pharmaceuticals, Inc. has a 12-month low of $12.06 and a 12-month high of $25.16.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million. Analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).